At the DIA EuroMeeting in Amsterdam today, Synteract, a Carlsbad, CA-based contract research organization (CRO), says it has acquired Harrison Clinical Research, an international CRO based in Munich, Germany. The combined company will operate globally as SynteractHCR, with offices in Western and Eastern Europe, Israel, Russia, South America, and the U.S.
Financial terms of the deal were not disclosed. Gryphon Investors, a San Francisco private equity firm with a stake in Synteract, led the HCR acquisition.
With a combined staff of more than 800, SynteractHCR says it will be a top-tier service provider with the scale to support large, late-stage programs across multiple clinical areas, including oncology, central nervous system, infectious disease, endocrinology, cardiovascular, and respiratory. In a statement, SynteractHCR says it plans to maintain a strong connection with “emerging to midsize biopharmaceutical companies through which a consultative approach and strong clinical development expertise provide the foundation of its customer relationships.”
The company plans to maintain its corporate headquarters in the San Diego area, led by Synteract CEO Wendell Barr. Francisco Harrison, who was the founder and chairman of HCR, will become a board member at SynteractHCR and a senior member of the executive team. Synteract COO Stewart Bieler will oversee U.S. operations and former HCR CEO Benedikt van Nieuwenhove will oversee European operations.
By posting a comment, you agree to our terms and conditions.